The fund purchased 27,685 shares of the biotechnology company’s stock, valued at approximately $3,269,000. Smith Graham & Co. Investment …

The biotechnology company reported $4.36 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.38 by $0.98.

… Arrowhead Pharmaceuticals Inc, Assembly Biosciences Inc, Beijing Kawin Technology Share-Holding Co Ltd, Beijing Minhai Biotechnology Co Ltd, …

Puma Biotechnology Inc. (NYSE:PBYI) has earned an average rating of “Buy” from the ten ratings firms that are currently covering the company.

The firm presently has a $2.25 target price on the biotechnology company’s stock. Zacks Investment Research’s price objective would indicate a …

Mr. Wilkins warned Chinese policy advisors that biotech approval delays would not only hurt growers and seed developers, but the environment and …

The fund owned 395,208 shares of the biotechnology company’s stock after buying an additional 75,214 shares during the period. Teachers Advisors …

The fund owned 357,364 shares of the biotechnology company’s stock after buying an additional 8,533 shares during the period. Rhumbline Advisers’ …

Puma Biotechnology Inc (NYSE:PBYI) shares have been stated a daily sentiment score of 0.56 for web articles published on 2016-12-09. This is …

In looking at the Value Composite score for Generex Biotechnology Corporation (OTCPK:GNBT), we see that the firm has a rank of 97. This is based …